96X.F FLUOGUIDE A/S DK -1
- Market cap
- EUR 40.7M
- P/E
- -
- P/B
- 10.12x
- ROE
- -160.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 96X.F undervalued?
Graham numberThe Graham number of FLUOGUIDE A/S DK -1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
FLUOGUIDE A/S DK -1 fundamental analysis
No fundamental analysis for FLUOGUIDE A/S DK -1 yet.
FLUOGUIDE A/S DK -1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a coll…
Full company profileFLUOGUIDE A/S DK -1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
FLUOGUIDE A/S DK -1 annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -28.8M | -32.5M | -43.9M | -33.0M | -39.8M | -56.4M |
| EBITDA | - | -32.4M | -43.6M | -33.9M | -44.3M | -54.3M |
| Net Income | -23.8M | -27.3M | -38.4M | -29.0M | -39.5M | -49.2M |
| EPS | -2.10 | -2.31 | -3.14 | -2.13 | -2.41 | -3.01 |
| Balance Sheet | ||||||
| Total Assets | 53.3M | 35.6M | 29.6M | 28.4M | 88.3M | 65.1M |
| Total Liabilities | 14.6M | 3.65M | 16.9M | 5.31M | 33.8M | 34.4M |
| Shareholders' Equity | 38.7M | 32.0M | 12.7M | 23.1M | 54.5M | 30.7M |
| Cash & Short-term Investments | 46.8M | 26.0M | 21.7M | 18.6M | 48.8M | 19.8M |
| Cash Flow | ||||||
| Operating Cash Flow | -15.1M | -37.6M | -31.8M | -29.2M | -37.0M | -56.4M |
| Capital Expenditure | 0.00 | 64.0K | 0.00 | 850K | 0.00 | 0.00 |
| Free Cash Flow | -15.1M | -37.7M | -31.8M | -30.0M | -37.0M | -56.4M |
| Ratios | ||||||
| ROE | -61.4% | -85.5% | -301.7% | -125.5% | -72.4% | -160.4% |
| ROA | -44.6% | -76.8% | -129.6% | -102.0% | -44.7% | -75.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
FLUOGUIDE A/S DK -1 dividends
FLUOGUIDE A/S DK -1 has not paid dividends in the last 5 fiscal years.
Who owns FLUOGUIDE A/S DK -1
- Insiders 24.94%
- Institutions 10.47%
- Public & others 64.59%
- Shares outstanding 16.3M
- Free float 12.3M
FLUOGUIDE A/S DK -1 company profile
- Company name
- FLUOGUIDE A/S DK -1
- Ticker
- 96X.F
- ISIN
- DK0061123312
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 6
- Fiscal year end
- December
- Address
- Titanhus, Titangade 9-13, Copenhagen, Denmark, 2200
- Phone
- 45 31 22 66 60
- Website
- fluoguide.com
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatment of brain cancer through photothermal and photodynamic therapies. It has a collaboration agreement with Olympus and ZEISS Medical Technologies for the development of FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The company was incorporated in 2018 and is based in Copenhagen, Denmark.
FLUOGUIDE A/S DK -1 management
4- Mr. Morten Albrechtsen B.B.A., M.D.Chief Executive Officer · born 1964
- Mr. Ole Larsen Cand. merc., M.Sc.Chief Financial Officer · born 1965
- Ms. Donna HaireChief Operating Officer · born 1969
- Prof. Andreas Kjaer M.D., M.Sc., Ph.D.CSO, Head of Scientific Advisory Board & Director · born 1963